Login to Your Account



Deals And M&A NEWS
Vical Inc. is moving to expand its infectious disease portfolio by in-licensing a trial-ready antifungal from Astellas Pharma Inc. that could complement a DNA-based cytomegalovirus (CMV) vaccine on which the companies already collaborate.
If anyone still doubted the power of chimeric antigen receptor T-cell (CAR T) technology to propel pipelines and stock prices, they needed look no further than the cross-country deal between Coronado Biosciences Inc. and the City of Hope to advance a portfolio of assets in newly created Mustang Therapeutics Inc.

DUBLIN – Danish biotech bellwether Genmab A/S and Swedish specialty pharma firm Pharmalink AB both added new preclinical projects to their respective pipelines Wednesday.

More Deals And M&A Headlines

Cast Your Vote

Has biotech’s bubble burst?: